Li Wenfeng, Wu Junyi, Hu Zijian, Zhang Jixuan, Ye Guangming, Luo Fengling, Zeng Zhikun, Luo Yi
Department of General Surgery, Liver Transplantation Centers, Huashan Hospital, Fudan University, Shanghai, China.
The Second Clinical College of Wuhan University, Wuhan, Hubei, China.
Front Pharmacol. 2025 Apr 28;16:1553337. doi: 10.3389/fphar.2025.1553337. eCollection 2025.
Ischemic stroke is a leading cause of death and disability worldwide. Therefore, there is a critical need to explore the underlying mechanisms and develop effective treatment strategies for ischemic stroke. As small and non-immunogenic nucleic acid molecules, aptamers can be easily chemically modified, break through the blood-brain barrier, and be screened using the classic Systematic Evolution of Ligands by Exponential Enrichment. With the advancements in emerging technologies, aptamer-based strategies have provided diagnostic and therapeutic potential for applications in central nervous system diseases. Aptamers have become a useful tool for targeted therapy and biomarker discovery in ischemic stroke. This review presents recent advances and perspectives on aptamer applications in stroke prevention, treatment, and diagnosis, focusing on targeting pathological blood clotting or thrombosis, inflammatory responses, and specific biomarkers in key cells.
缺血性中风是全球死亡和残疾的主要原因。因此，迫切需要探索其潜在机制并开发有效的缺血性中风治疗策略。作为小的非免疫原性核酸分子，适体可以很容易地进行化学修饰，突破血脑屏障，并通过经典的指数富集配体系统进化法进行筛选。随着新兴技术的进步，基于适体的策略为中枢神经系统疾病的应用提供了诊断和治疗潜力。适体已成为缺血性中风靶向治疗和生物标志物发现的有用工具。本文综述了适体在中风预防、治疗和诊断中的应用的最新进展和前景，重点关注靶向病理性凝血或血栓形成、炎症反应以及关键细胞中的特定生物标志物。
